Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.

Cha Y, Kim SY, Yeo HY, Baek JY, Choi MK, Jung KH, Dong SM, Chang HJ.

Neoplasia. 2019 Jan;21(1):146-155. doi: 10.1016/j.neo.2018.11.010. Epub 2018 Dec 15.

2.

WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.

Bosch LJ, Luo Y, Lao VV, Snaebjornsson P, Trooskens G, Vlassenbroeck I, Mongera S, Tang W, Welcsh P, Herman JG, Koopman M, Nagtegaal ID, Punt CJ, van Criekinge W, Meijer GA, Monnat RJ Jr, Carvalho B, Grady WM.

Clin Cancer Res. 2016 Sep 15;22(18):4612-22. doi: 10.1158/1078-0432.CCR-15-2703. Epub 2016 Apr 27.

3.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R 2nd, Azad N, Kopetz S.

Ann Oncol. 2018 Jan 1;29(1):139-144. doi: 10.1093/annonc/mdx688. Erratum in: Ann Oncol. 2019 Mar 1;30(3):495.

4.

CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.

Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS.

Virchows Arch. 2007 May;450(5):529-37. Epub 2007 Mar 20.

PMID:
17372756
5.

Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma.

Hu SL, Kong XY, Cheng ZD, Sun YB, Shen G, Xu WP, Wu L, Xu XC, Jiang XD, Huang DB.

Tumori. 2010 Sep-Oct;96(5):726-33.

PMID:
21302620
6.

Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.

Cha Y, Kim KJ, Han SW, Rhee YY, Bae JM, Wen X, Cho NY, Lee DW, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Kang GH, Kim TY.

Br J Cancer. 2016 Jul 12;115(2):164-71. doi: 10.1038/bjc.2016.176. Epub 2016 Jun 16.

7.

CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.

Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG, Azad NS.

Int J Cancer. 2014 Feb 1;134(3):596-605. doi: 10.1002/ijc.28390. Epub 2013 Aug 24.

8.

Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.

Zhou JD, Zhang TJ, Li XX, Ma JC, Guo H, Wen XM, Yao DM, Zhang W, Lin J, Qian J.

J Cell Physiol. 2018 Jun;233(6):4707-4714. doi: 10.1002/jcp.26253. Epub 2018 Jan 15.

PMID:
29115660
9.

Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.

Cheng ZD, Hu SL, Sun YB, Xu WP, Shen G, Kong XY.

Chin J Cancer. 2010 Feb;29(2):163-6.

10.

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.

Cohen SA, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, Grady WM.

Clin Colorectal Cancer. 2016 Jun;15(2):164-9. doi: 10.1016/j.clcc.2015.10.005. Epub 2015 Nov 11.

11.

Predictive value of CHFR and MLH1 methylation in human gastric cancer.

Li Y, Yang Y, Lu Y, Herman JG, Brock MV, Zhao P, Guo M.

Gastric Cancer. 2015 Apr;18(2):280-7. doi: 10.1007/s10120-014-0370-2. Epub 2014 Apr 21.

12.

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.

Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.

Int J Cancer. 2013 May 1;132(9):2209-16. doi: 10.1002/ijc.27888. Epub 2012 Oct 29.

13.

Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.

Baba S, Hara A, Kato K, Long NK, Hatano Y, Kimura M, Okano Y, Yamada Y, Shibata T.

Oncol Rep. 2009 Nov;22(5):1173-9.

PMID:
19787237
14.

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.

Zhang X, Shimodaira H, Soeda H, Komine K, Takahashi H, Ouchi K, Inoue M, Takahashi M, Takahashi S, Ishioka C.

Int J Clin Oncol. 2016 Dec;21(6):1091-1101. Epub 2016 Jul 19.

PMID:
27435270
15.

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ Jr, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM; Alliance for Clinical Trials in Oncology.

Gastroenterology. 2014 Sep;147(3):637-45. doi: 10.1053/j.gastro.2014.05.009. Epub 2014 May 21.

16.

CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.

Cleven AH, Derks S, Draht MX, Smits KM, Melotte V, Van Neste L, Tournier B, Jooste V, Chapusot C, Weijenberg MP, Herman JG, de Bruïne AP, van Engeland M.

Clin Cancer Res. 2014 Jun 15;20(12):3261-71. doi: 10.1158/1078-0432.CCR-12-3734.

17.

CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.

Kawasaki T, Ohnishi M, Nosho K, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, Ogino S.

Mod Pathol. 2008 Mar;21(3):245-55. doi: 10.1038/modpathol.3800982. Epub 2008 Jan 18.

18.

[Aberrant promoter hypermethylation of CHFR in nasopharyngeal carcinoma].

Huang T, Du C, Yu N, Xiao X, Zhou X, Wang S, Huang G, Zhang Z.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Aug;25(16):746-50. Chinese.

PMID:
22070084
19.

Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.

Morioka Y, Hibi K, Sakai M, Koike M, Fujiwara M, Kodera Y, Ito K, Nakao A.

Anticancer Res. 2006 Nov-Dec;26(6B):4267-70.

20.

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.

Demurtas L, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Mandolesi A, Cremolini C, Masi G, Gelsomino F, Antoniotti C, Loretelli C, Meriggi F, Zaniboni A, Falcone A, Cascinu S, Scartozzi M.

Br J Cancer. 2017 Jul 25;117(3):315-321. doi: 10.1038/bjc.2017.178. Epub 2017 Jun 20.

Supplemental Content

Support Center